Fumarate Hydratase Deficient Renal Cell Carcinoma
3 clinical trials · Condition
◉ Watch Fumarate Hydratase Deficient Renal Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma (NCT04068831) | Memorial Sloan Kettering Cancer Center | 2019-08-22 |
| A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma (NCT03635892) | Memorial Sloan Kettering Cancer Center | 2018-08-13 |
Track Fumarate Hydratase Deficient Renal Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.